BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 12744471)

  • 1. Promoter hypermethylation of the DNA repair gene O6-methylguanine-DNA methyltransferase is an independent predictor of shortened progression free survival in patients with low-grade diffuse astrocytomas.
    Komine C; Watanabe T; Katayama Y; Yoshino A; Yokoyama T; Fukushima T
    Brain Pathol; 2003 Apr; 13(2):176-84. PubMed ID: 12744471
    [TBL] [Abstract][Full Text] [Related]  

  • 2. O6-methylguanine-DNA methyltransferase methylation and TP53 mutation in malignant astrocytomas and their relationships with clinical course.
    Watanabe T; Katayama Y; Komine C; Yoshino A; Ogino A; Ohta T; Fukushima T
    Int J Cancer; 2005 Feb; 113(4):581-7. PubMed ID: 15455376
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Promoter methylation of the DNA repair gene MGMT in astrocytomas is frequently associated with G:C --> A:T mutations of the TP53 tumor suppressor gene.
    Nakamura M; Watanabe T; Yonekawa Y; Kleihues P; Ohgaki H
    Carcinogenesis; 2001 Oct; 22(10):1715-9. PubMed ID: 11577014
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Aberrant hypermethylation of p14ARF and O6-methylguanine-DNA methyltransferase genes in astrocytoma progression.
    Watanabe T; Katayama Y; Yoshino A; Yachi K; Ohta T; Ogino A; Komine C; Fukushima T
    Brain Pathol; 2007 Jan; 17(1):5-10. PubMed ID: 17493032
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hypermethylation of O6-methylguanine-DNA methyltransferase promoter may predict nonrecurrence after chemotherapy in colorectal cancer cases.
    Nagasaka T; Sharp GB; Notohara K; Kambara T; Sasamoto H; Isozaki H; MacPhee DG; Jass JR; Tanaka N; Matsubara N
    Clin Cancer Res; 2003 Nov; 9(14):5306-12. PubMed ID: 14614014
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Promoter hypermethylation of the DNA-repair gene O6-methylguanine-DNA methyltransferase and p53 mutation in diffuse large B-cell lymphoma.
    Hiraga J; Kinoshita T; Ohno T; Mori N; Ohashi H; Fukami S; Noda A; Ichikawa A; Naoe T
    Int J Hematol; 2006 Oct; 84(3):248-55. PubMed ID: 17050200
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents.
    Esteller M; Garcia-Foncillas J; Andion E; Goodman SN; Hidalgo OF; Vanaclocha V; Baylin SB; Herman JG
    N Engl J Med; 2000 Nov; 343(19):1350-4. PubMed ID: 11070098
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The interplay mechanism between IDH mutation, MGMT-promoter methylation, and PRMT5 activity in the progression of grade 4 astrocytoma: unraveling the complex triad theory.
    Kurdi M; Alkhotani A; Sabbagh A; Faizo E; Lary AI; Bamaga AK; Almansouri M; Hafiz B; Alsharif T; Baeesa S
    Oncol Res; 2024; 32(6):1037-1045. PubMed ID: 38827324
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Correlation between promoter hypermethylation of the O6-methylguanine-deoxyribonucleic acid methyltransferase gene and prognosis in patients with high-grade astrocytic tumors treated with surgery, radiotherapy, and 1-(4-amino-2-methyl-5-pyrimidinyl)methyl-3-(2-chloroethyl)-3-nitrosourea-based chemotherapy.
    Kamiryo T; Tada K; Shiraishi S; Shinojima N; Kochi M; Ushio Y
    Neurosurgery; 2004 Feb; 54(2):349-57; discussion 357. PubMed ID: 14744281
    [TBL] [Abstract][Full Text] [Related]  

  • 10. O-methylguanine-DNA methyltransferase (MGMT) mRNA expression predicts outcome in malignant glioma independent of MGMT promoter methylation.
    Kreth S; Thon N; Eigenbrod S; Lutz J; Ledderose C; Egensperger R; Tonn JC; Kretzschmar HA; Hinske LC; Kreth FW
    PLoS One; 2011 Feb; 6(2):e17156. PubMed ID: 21365007
    [TBL] [Abstract][Full Text] [Related]  

  • 11. DNA repair gene O6-methylguanine-DNA methyltransferase: promoter hypermethylation associated with decreased expression and G:C to A:T mutations of p53 in brain tumors.
    Yin D; Xie D; Hofmann WK; Zhang W; Asotra K; Wong R; Black KL; Koeffler HP
    Mol Carcinog; 2003 Jan; 36(1):23-31. PubMed ID: 12503076
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Promoter hypermethylation of the DNA repair gene O(6)-methylguanine-DNA methyltransferase is associated with the presence of G:C to A:T transition mutations in p53 in human colorectal tumorigenesis.
    Esteller M; Risques RA; Toyota M; Capella G; Moreno V; Peinado MA; Baylin SB; Herman JG
    Cancer Res; 2001 Jun; 61(12):4689-92. PubMed ID: 11406538
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic significance of O6-methylguanine-DNA methyltransferase determined by promoter hypermethylation and immunohistochemical expression in anaplastic gliomas.
    Brell M; Tortosa A; Verger E; Gil JM; Viñolas N; Villá S; Acebes JJ; Caral L; Pujol T; Ferrer I; Ribalta T; Graus F
    Clin Cancer Res; 2005 Jul; 11(14):5167-74. PubMed ID: 16033832
    [TBL] [Abstract][Full Text] [Related]  

  • 14. O6-methylguanine DNA methyltransferase gene promoter methylation status in gliomas and its correlation with other molecular alterations: first Indian report with review of challenges for use in customized treatment.
    Jha P; Suri V; Jain A; Sharma MC; Pathak P; Jha P; Srivastava A; Suri A; Gupta D; Chosdol K; Chattopadhyay P; Sarkar C
    Neurosurgery; 2010 Dec; 67(6):1681-91. PubMed ID: 21107199
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Therapeutic efficacy and prognostic factors in diffuse astrocytomas].
    Watanabe T; Komine C; Yokoyama T; Yoshino A; Katayama Y
    No Shinkei Geka; 2003 Jul; 31(7):767-73. PubMed ID: 12884791
    [TBL] [Abstract][Full Text] [Related]  

  • 16. O(6)-Methylguanine-DNA methyltransferase promoter hypermethylation shifts the p53 mutational spectrum in non-small cell lung cancer.
    Wolf P; Hu YC; Doffek K; Sidransky D; Ahrendt SA
    Cancer Res; 2001 Nov; 61(22):8113-7. PubMed ID: 11719438
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hypermethylation of the DNA repair gene O(6)-methylguanine DNA methyltransferase and survival of patients with diffuse large B-cell lymphoma.
    Esteller M; Gaidano G; Goodman SN; Zagonel V; Capello D; Botto B; Rossi D; Gloghini A; Vitolo U; Carbone A; Baylin SB; Herman JG
    J Natl Cancer Inst; 2002 Jan; 94(1):26-32. PubMed ID: 11773279
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical trial substantiates the predictive value of O-6-methylguanine-DNA methyltransferase promoter methylation in glioblastoma patients treated with temozolomide.
    Hegi ME; Diserens AC; Godard S; Dietrich PY; Regli L; Ostermann S; Otten P; Van Melle G; de Tribolet N; Stupp R
    Clin Cancer Res; 2004 Mar; 10(6):1871-4. PubMed ID: 15041700
    [TBL] [Abstract][Full Text] [Related]  

  • 19. O(6) -methylguanine-DNA methyltransferase (MGMT) promoter methylation and low MGMT-encoded protein expression as prognostic markers in glioblastoma patients treated with biodegradable carmustine wafer implants after initial surgery followed by radiotherapy with concomitant and adjuvant temozolomide.
    Lechapt-Zalcman E; Levallet G; Dugué AE; Vital A; Diebold MD; Menei P; Colin P; Peruzzy P; Emery E; Bernaudin M; Chapon F; Guillamo JS
    Cancer; 2012 Sep; 118(18):4545-54. PubMed ID: 22359215
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Correlation between quantified promoter methylation and enzymatic activity of O6-methylguanine-DNA methyltransferase in glioblastomas.
    Kishida Y; Natsume A; Toda H; Toi Y; Motomura K; Koyama H; Matsuda K; Nakayama O; Sato M; Suzuki M; Kondo Y; Wakabayashi T
    Tumour Biol; 2012 Apr; 33(2):373-81. PubMed ID: 22274924
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.